Αναζήτηση

σε πρόσθεσε στο Health

2026-10-23 19:35:08 - Μετάφραση -

Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease tests

Roth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...

0 Σχόλια 0 Μοιράστηκε 7 Views 0 Προεπισκόπηση